RMC-4550 is a potent, selective and allosteric inhibitor of SHP2 enzyme with IC50 value of 0.58 nM, without activity against the SHP2 catalytic domain up to a concentration of 10 µM. RMC-4550 exhibited preferential inhibition in cell lines bearing the G12C mutation and potently suppressed pERK in Calu-1 cells at concentration <10μM. RMC-4550 both inhibited cell proliferation and suppressed RAS-GTP and pERK levels in NCI-H358 (lung, KRASG12C/+) and MIA PaCa-2 (pancreas, KRASG12C/G12C) cell lines. RMC-4550 led to caspase 3/7 activation at concentration of 1 and 10μM, indicative of a pro-apoptotic effect in NCI-H358 cells. Oral administration of RMC-4550 dose-dependently inhibited tumor growth in NCI-H358 xenograft mice at dose of 3, 10 and 30mg/kg, qd, and in MIA PaCa-2 xenograft mice at 10, 30 and 60mg/kg, qd, in MIA PaCa-2 xenograft mice, both of which are models of KRASG12C-driven cancer, with downregulated p-ERK observed[1].
作用机制
RMC-4550 is an allosteric inhibitor of SHP2 enzyme. It downregulated RAS-GTP by disrupting the SHP2/SOS1/GRB2 module that is required for GTP-loading of RAS.[1][2]
RMC-4550 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Organotypic slice cultures
0.05 µM–5 µM
To assess the modulating effect of RMC-4550 on gene expression in the context of neuroinflammation.
J Neuroinflammation. 2024 Jan 31;21(1):37.
RMC-4550 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
KCP mice
Oral gavage
10 mg/kg
Daily for 21 days
Demonstrated a synergistic effect in tumor reduction.
搜索
